Silo Pharma

Historical price data

Silo Pharma is a Nasdaq-listed biotech focused on developing novel therapeutics for central nervous system disorders and chronic pain through a capital-efficient licensing and development model. Its core strategy involves in-licensing promising candidates from academic partners and advancing them via the FDA's 505(b)(2) regulatory pathway to reduce time and cost. Key assets include SPC-15, a prophylactic intranasal treatment for stress-induced disorders, and SP-26, a ketamine-based implant for fibromyalgia. The company aims to address significant unmet medical needs in large, growing markets with limited treatment options.

Silo's technological approach combines innovative drug delivery systems (e.g., intranasal 'nose-to-brain', sustained-release implants) with a strategic focus on the FDA's 505(b)(2) regulatory pathway for novel formulations of established drug compounds.

Silo competes in crowded fields against large pharma, generic drugs, and a wave of new neuro-focused biotechs. Its differentiation hinges on its non-psychedelic prophylactic approach (SPC-15), sustained-release implant (SP-26), and capital-efficient development model, but it remains a small player with unproven clinical candidates.